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role for damage and protection of neurons in
the pathophysiology and treatment of psychiatric illness,
including major depressive disorder (MDD) is based on
molecular, cellular, and morphological studies in exper-
imental animals and in human patients. Preclinical stud-
ies demonstrate that chronic stress causes alterations to
the number and shape of neurons and glia in brain
regions implicated in mood disorders.
1-4 Advances in
human brain imaging have also reported decreased vol-
umes of limbic brain regions implicated in depression.
5,6
Preclinical and postmortem studies of signal transduc-
tion pathways and target genes have extended this work
at the molecular level, demonstrating dysregulation of
neurotrophic factors and neuroprotective mechanisms
in response to stress and in depressed patients.
1,2,7
Conversely, chronic administration of therapeutic agents
blocks the effects of stress or leads to induction of neu-
rotrophic and neuroprotective pathways.
2,8 Together,
these findings have contributed to a fundamental shift in
our understanding of the cause and treatment of psy-
chiatric illnesses and the role of neurotrophic and neu-
roprotective mechanisms. 
This review will present evidence demonstrating neu-
ronal damage, atrophy, and cell loss in response to stress
and depression, and the mechanisms underlying these
effects. Studies demonstrating the neuroprotective
actions of therapeutic agents that counteract the effects
of stress and depression will also be discussed. Related
aspects of this work are the effects of environment, cel-
lular stressors, insults, and interactions with genetic fac-
tors that increase susceptibility and thereby cause dam-
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The discovery that stress and depression, as well as other
psychiatric illnesses, are characterized by structural alter-
ations, and that these changes result from atrophy and
loss of neurons and glia in specific limbic regions and cir-
cuits, has contributed to a fundamental change in our
understanding of these illnesses. These structural changes
are accompanied by dysregulation of neuroprotective
and neurotrophic signaling mechanisms that are required
for the maturation, growth, and survival of neurons and
glia. Conversely, behavioral and therapeutic interventions
can reverse these structural alterations by stimulating
neuroprotective and neurotrophic pathways and by
blocking the damaging, excitotoxic, and inflammatory
effects of stress. Lifetime exposure to cellular and envi-
ronmental stressors and interactions with genetic factors
contribute to individual susceptibility or resilience. This
exciting area of research holds promise and potential for
further elucidating the pathophysiology of psychiatric ill-
ness and for development of novel therapeutic interven-
tions. 
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PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 239age and illness (Figure 1). Conversely, life history of
behavior or therapies that reduce stress and enhance
neuronal survival, such as exercise, diet, medications, and
interactions with genetic factors that increase resilience
are neuroprotective, and reverse or block the damaging
effects of stress. 
In addition, cellular growth and survival are intimately
controlled by neuronal activity (Figure 1). This is due to
the activity-dependent requirement for expression of
neurotrophic factors and other survival pathways and
mechanisms that control neurotransmission and neuro-
plasticity, as well as proliferation, growth, and survival. 
Structural/cellular alterations 
in mood disorders
Depression, like most other major psychiatric illnesses,
is widely accepted to be caused by neurochemical imbal-
ances in regions of the brain that are known to control
mood, anxiety, cognition, and fear. These regions include
the hippocampus, prefrontal cortex (PFC), cingulate cor-
tex, nucleus accumbens, and amygdala. In addition, brain
imaging and postmortem studies have identified struc-
tural alterations in MDD patients that indicate reduc-
tions in dendrite arborization and complexity, and
decreased numbers of neurons and glia in these brain
regions, all of which could contribute to depressive
symptoms (Figure 2). Together, these findings provide
compelling evidence for disruption of neurotrophic fac-
tors and neuroprotective mechanisms in the pathophys-
iology of depression.  
Structural alterations
One of the regions of interest in depression, as well as
other disorders, is the hippocampus, a structure that con-
tains high levels of receptors for glucocorticoids. Imaging
studies have consistently reported that the volume of 
the hippocampus is decreased 10% to 20% in MDD
patients.
9-12,13,14There is also evidence of a negative cor-
relation with the length of illness and reversal with anti-
depressant treatment (ADT),
15 but additional studies are
needed to further examine these relationships and to
determine whether the reduction is a result or a cause of
depressive illness. It is also notable that hippocampal
volume reductions have been reported in other stress-
related illnesses, including post-traumatic stress disorder
(PTSD)
16,17 and schizophrenic patients.
18
The PFC is another “stress-responsive” brain region
implicated in depression. The primary function of the
PFC is cognition, working memory, and inhibitory con-
trol of brain regions that underlie fear and emotion.
Brain imaging studies have reported a significant reduc-
tion in the volume of the PFC in MDD patients, which
could underlie the reported hypofunction of this struc-
ture, most notably decreased cognition.
9,15,19,20
Cellular alterations 
Different types of cellular alterations could account for
the volume reductions observed in the hippocampus,
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ADT antidepressant treatment
AMPA -amino-3-hydroxyl-5-methyl-4-isoxazole-propio-
nic acid
BDNF brain derived neurotrophic factor
IDO indoleamine 2,3-dioxygenase
MDD major depressive disorder
NMDA N-methyl-D-aspartic acid
PFC prefrontal cortex
TNF tumor necrosis factor
Figure 1. Schematic demonstrating the effects of stress and neuropro-
tective mechanisms on the proliferation, growth, and survival of
neurons and glia. Interactions with environment, genetic fac-
tors, and life history also influence these cellular processes, which
then regulate emotional and cognitive health or illness. Normal,
healthy activity of the brain circuits that underlie emotion and
cognition also influence cell survival and function as the expres-
sion and function of neurotrophic and neuroprotective mecha-
nisms requires neuronal activity.
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tion of neurons and glia. There is one report that the size
of neurons in the major subfields of the hippocampus is
reduced,
21 suggesting a reduction in neuropil that could
contribute to decreased hippocampal volume in MDD
patients. There were no changes in the numbers of neu-
rons or glia reported in this study or in other qualitative
studies, although more subtle synaptic changes have
been reported.
22
Studies of the PFC and cingulate cortex have been more
extensive, and have shown a reduction in the size of neu-
ronal cell bodies, suggestive of reduced dendritic
arborization and complexity.
23,24 In addition, the most
consistent finding in studies of PFC is a decrease in the
number of glia in MDD patients.
23-25 Reductions of both
astrocytes
26 and oligodendrocytes
27,28 have been reported.
Given the significant role of glia in providing metabolic
support for neurons as well as control of neurotrans-
mitter activity (eg, synthesis and reuptake), it is reason-
able to speculate that neuronal atrophy, damage, and
hypofunction of PFC could be related to the loss of glia.
Cellular alterations in 
animal models of depression
Animal models of depression have been used to further
elucidate the ultastructural and molecular alterations that
underlie the morphological changes observed in MDD
patients. Most of these models are based on acute or
chronic-stress paradigms, as stress is a critical factor in the
etiology of depression. In addition, these models have
been used to demonstrate that antidepressants can reverse
or block the effects of stress on cellular morphology, which
might contribute to the therapeutic actions of these agents.
Cell morphology
Early studies of cell morphology found that repeated
stress causes atrophy of CA3 pyramidal neurons in the
hippocampus, characterized by a decreased number and
length of apical dendrites.
29,30 More recent studies have
shown that pyramidal neurons in the PFC undergo a
similar retraction/atrophy of apical dendrites, and a
reduction in spine number in response to immobilization
stress (Figure 2).
31 Chronic exposure to high levels of
exogenous corticosterone, the rodent equivalent of cor-
tisol, causes a similar atrophy of hippocampal and PFC
neurons.
32,33
In contrast to most neurological disorders, in which the
structural alterations and loss of neurons is permanent,
the stress-induced atrophy of hippocampal and PFC
neurons is reversible. Most notably, removing animals
from stress normalizes the dendritic arborization of
pyramidal neurons over a period of several weeks.
3,32,34
Moreover, chronic administration of certain antidepres-
sants blocks or reverses hippocampal atrophy, even with
continued stress exposure.
29,30This reversibility supports
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Figure 2. Influence of stress on the morphology and proliferation of neu-
rons and neurotrophic factor expression. Exposure to immobi-
lization stress decreases the number and length of pyramidal cell
apical dendrites, and the number of spines in the prefrontal cor-
tex (PFC). Stress also decreases the birth of new neurons and
expression of brain derived neurotrophic factor (BDNF) in the
adult hippocampus (HP). Images courtesy of Drs G. Aghajanian
and R-J. Li.
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structural plasticity that has functional consequences. 
Cell proliferation 
In addition to dendritic atrophy, chronic stress decreases
the proliferation of new cells in the adult hippocampus
and PFC. The dentate gyrus of the hippocampus is one
of the few regions of the brain that continues to give rise
to new neurons in adulthood, in rodents as well as non-
human primates and humans.
35,36 Interestingly, the rate
of neurogenesis is influenced by environmental and
endocrine factors, and stress is one of the most consis-
tent and robust negative regulators (Figure 2). The pro-
liferation of new neurons is decreased by different types
of stress, including restraint, footshock, maternal sepa-
ration, predator odor, psychosocial stress, and sleep
deprivation, and by administration of exogenous corti-
costerone.
37 In the PFC the proliferation of glia is
decreased by exposure to repeated stress
38 or corticos-
terone treatment.
39 Chronic stress also decreases the
number of glial fibrillary acidic protein (GFAP)-positive
astrocytes in the hippocampus.
40
In contrast, antidepressants increase the proliferation of
neurons and glia in the hippocampus and/or PFC, and
block or reverse the effects of stress.
37,38,41,42These effects
require chronic administration (weeks), consistent with
the time course for the therapeutic response to antide-
pressants. Different classes of antidepressant increase
cell proliferation in rats, including serotonin selective
transporter inhibitors, norepinephrine selective reuptake
inhibitors (NSRIs), and electroconvulsive seizures
(ECS),
41,43,44 indicating that this is a common target of
ADT.
Behavioral consequences of altered cell morphology
A major question is whether the cellular alterations lead
to changes in behavior. This has been addressed by
blockade studies (ie, focused irradiation or genetic
manipulation), which demonstrate that neurogenesis is
required for the actions of antidepressants in certain
behavioral models,
42,45,46 although there are exceptions.
47,48
Ablation of glia in the PFC decreases sucrose consump-
tion, a measure of anhedonia, indicating a requirement
for glial function in this model.
49 Decreased PFC den-
drite arborization in response to stress is also correlated
with a reduction in attention set shifting, a PFC-depen-
dent behavior.
50 These studies demonstrate a causal
and/or correlative relationship between cell number and
complexity with behavior. 
Importance of life stress/trauma: gene-environment
interactions
There is also evidence that exposure to traumatic or
stressful life events can have a cumulative effect that
increases susceptibility or vulnerability to mood disor-
ders
51 (see Figure 1). Interactions of stress and genetic
factors have also been reported, most notably for life-
time stress and the serotonin (5-HT) transporter short
allele polymorphism
52; however, a recent meta-analysis
suggests that additional studies of this polymorphism are
required.
53 Studies of genes that increase resilience to
stress and mood disorders have also been conducted.
54
Recent studies have also reported an interaction
between early life stress or trauma and neurotrophic fac-
tors (see below).
Mechanisms underlying structural 
alterations and neuroprotection: 
gene-environment interactions
Cellular and structural alterations in response to stress,
depression, and antidepressant medications could result
from a number of different mechanisms that alter the
proliferation, growth, survival, and function of neurons
and glia. These include altered neurotrophic/growth fac-
tor support, excitotoxicity, inflammation/cytokines, meta-
bolic/vascular support, viral, and toxic insults. The influ-
ence of these factors and insults on cell function and
survival could occur rapidly after a single major event or
could occur gradually over time with the accumulation
of one or more insults, also referred to as allostatic load
(Figure 1).
55
The effects of these cellular stressors and insults are also
influenced by genetic factors that can either increase sus-
ceptibility to cellular damage, or conversely decrease
susceptibility and increase resilience and neuroprotec-
tion. This complex interaction of gene-environment
interactions over the lifespan is thought to contribute to
the heterogeneity of depression, other psychiatric ill-
nesses, as well as treatment of these disorders.
Characterization of the molecular mechanisms and
genetic factors that underlie the structural alterations
and that play a key role in neuroprotection will provide
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of depression. 
The following sections will discuss the major molecular
and cellular mechanisms underlying the actions of stress,
depression, and ADT. The latter will include not only
chemical antidepressants, but also other strategies that
have neuroprotective actions, including exercise. As dis-
cussed above, postmortem studies demonstrate a decrease
in the size, but not the number, of neurons, indicating that
cell death probably does not play a major role in depres-
sion. These findings suggest that mechanisms that control
maintenance of neuronal size and function, and counter-
act stress-induced atrophy, such as neurotrophic factors,
could be critical mediators. Other important mechanisms
to be discussed are glutamate excitoxicity, apoptosis, and
inflammation/immune responses.
Neurotrophic/growth factors
The nerve growth factor (NGF) family has been the
focus of much of the work on stress and depression, and
the most widely studied member of this family is brain
derived neurotrophic factor (BDNF). In addition, sev-
eral other growth factors, including VEGF, IGF-1, and
FGF2 have also been implicated in the effects of stress,
depression, and ADT. Because these factors play a crit-
ical role in the proliferation, growth, and survival of neu-
rons and glia in the adult brain, their altered expression
or function could contribute to the cellular and mor-
phological changes in animal models of depression and
in MDD patients. This section will review key evidence
demonstrating dysregulation of neurotrophic/growth
factors in stress and depression.
Role of BDNF in stress, depression, and ADT
BDNF and related family members, including NGF and
neurotrophin-3 (NT-3), influence the proliferation, differ-
entiation, and growth of neurons during development, but
are also expressed in the adult brain and play a critical role
in the survival and function of mature neurons.
56 BDNF is
expressed at relatively high levels in limbic brain structures
implicated in mood disorders, including the hippocampus,
PFC, and amygdala, and acts through a transmembrane
tyrosine kinase receptor referred to as TrkB. Functional
BDNF acts as a dimer to stimulate the intracellular tyro-
sine kinase domain of TrkB, resulting in autophosphoryla-
tion of the receptor and interactions with docking proteins
that lead to activation of one of three major intracellular
signaling cascades: the microtubule associated protein
kinase (MAPK), the phosphatidylinositol-3 kinase (PI-
3K), and the phospholipase-C-γ (PLCγ) pathways (Figure
3).
8These cascades have been linked to the neuroprotec-
tive effects of BDNF, as well as regulation of cell prolifer-
ation, differentiation, and survival.
56
Stress, depression, and regulation of BDNF
Smith and colleagues were the first to report that expo-
sure to immobilization stress results in a dramatic reduc-
tion in levels of BDNF in the rodent hippocampus,
57 and
this effect has been reported with many other types of
stress.
1 Decreased expression of BDNF is observed in
the major subfields of the hippocampus, including those
layers where dendritic atrophy (CA3 pyramidal cell
layer) and decreased neurogenesis (dentate gyrus gran-
ule cell layer) are observed in response to stress.
57
Expression of BDNF in the PFC is also decreased by
chronic, but not acute stress.
58 Postmortem studies are
consistent with the rodent work, reporting decreased
levels of BDNF in the hippocampus of suicide-MDD
subjects.
59-61 These findings provide further support for
the hypothesis that the morphological and behavioral
abnormalities associated with MDD could result, in part,
from decreased BDNF expression. 
There are several possible mechanisms that could under-
lie the regulation of BDNF by stress. This includes a
reduction of neuronal firing, as BDNF expression is
dependent on activity and Ca
2+-stimulated gene tran-
scription.
62 BDNF expression is also decreased by
adrenal-glucocorticoids, which are induced by stress and
activation of the hypothalamo-pituitary-adrenal (HPA)
axis.
57 There is also evidence that downregulation of
BDNF by acute stress is mediated by interleukin-1β (IL-
1β),
63 and epigenetic regulation of BDNF expression in
response to chronic social defeat stress.
64
Genetic studies of BDNF and interactions with stress
A relationship between BDNF, morphology, and behav-
ior is supported by genetic studies of BDNF. Most of this
work has focused on a functional polymorphism,
Val66Met, that decreases the processing and release of
BDNF.
65The Met allele has been associated with reduced
hippocampal size and decreased memory and executive
function in humans.
65-67The met allele has also been asso-
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Figure 3. Regulation of neurotrophic/growth factors signaling is decreased by stress and increased by antidepressant treatment.  Activation of these
pathways leads to neuroprotection, survival, resilience, Antiapoptosis, and proliferation of neurons and glia in limbic brain regions. 5-HT, 5-
hydroxytryptamine; NE, norepinephrine; GPCR, G protein coupled receptor; AC, adenylyl cyclase; Gs, stimulatory G protein; cAMP, cyclic adeno-
sine 3’,5’-monophosphate; PKA, cAMP-dependent protein kinase; CREB, cAMP response element binding protein; VEGF, vascular endothe-
lial growth factor; IGF-1, insulin-like growth factor-1; FGF2, fibroblast growth factor-2; BDNF, brain derived neurotrophic factor; IRS, insulin
receptor substrate ; FRS, fibroblast growth factor receptor substrate; Grb2, adaptor protein; Sos, guanine nucleotide exchange factor; PI-3K,
phosphatidylinositol 3’-kinase; Akt, protein kinase B, serine.threonine kinase; GSK-3, glycogen synthase kinase-3; Bad, proapoptotic factor;
Ras, small guanosine triphosphatase; Raf, serine/threonine kinase; MEK, ERK kinase; ERK, extracellular signal regulated kinase; Rsk, ribosomal
S6 kinase; Shc, Src homology domain adaptor protein; IL-1b, interleukin-1b; IKK, kappaB inhibitory protein kinase; IkB, kappaB inhibitory pro-
tein; NFkB, nuclear factor kappaB; Bcl2, antiapoptotic factor
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effect is greater in patients with bipolar disorder.
68There
are also reports that patients carrying the Met allele,
either young or aged, have an increased incidence of
depression when exposed to stress or trauma.
69-71These
latter studies highlight the importance of gene x envi-
ronment interactions in complex, multifactorial illnesses
such as depression.
Evidence for a direct relationship between the Met
allele and neuronal structure has also been reported in
rodent models. In mice expressing the Met allele there
is a decrease in the number and length of apical den-
drites in both the hippocampus
72 and PFC,
73 similar to
the actions of stress.
73,74
Although deletion of BDNF is not sufficient to produce
depressive-like behaviors, except in female mice,
75-77
blockade or reduction of BDNF expression increases the
susceptibility to the effects of stress. Exposure of BDNF
heterozygous deletion mutant mice to stress or blockade
of BDNF-TrkB signaling produces a depressive-like phe-
notype in the forced swim test.
78 A gene-environment
interaction is also supported by the genetic association
studies of the BDNF Met allele discussed above.
70,71
A complicating factor in understanding the functions of
trophic factors is the possibility that there are opposing,
region-specific effects of BDNF. This is based on studies
demonstrating that BDNF is increased by stress in the
mesolimbic dopamine system and has a depressive effect
in the social defeat model, and conversely, that ADT
decreases BDNF in this reward pathway.
79 These find-
ings demonstrate that the expression and function of
BDNF, and possibly other trophic factors, is circuit-
dependent and that findings in one region cannot be
extrapolated to others. 
Antidepressants increase BDNF
In contrast to the effects of stress, chronic, but not acute
ADT increases the expression of BDNF in the hip-
pocampus and frontal cortex.
1,80-82 Induction of BDNF is
observed with different classes of chemical antidepres-
sants as well as electroconvulsive seizures.
1,80,82,83 Other
agents known to have antidepressant efficacy also
increase BDNF expression in the hippocampus, including
α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid
(AMPA) receptor potentiators, NMDA receptor antago-
nists, transcranial magnetic stimulation, and exercise.
1
These findings indicate that increased expression of
BDNF is a common target for different therapeutic
strategies. Postmortem studies also demonstrate that
BDNF levels are increased in the hippocampus of
patients receiving antidepressant medication at the time
of death, demonstrating the clinical relevance of ADT
induction of BDNF.
59These effects are thought to occur
via activation of cAMP and/or Ca
2+-dependent BDNF
gene transcription that are activated by ADT.
84-86
Neuroprotective, neurogenic, and behavioral actions of
BDNF
The neuroprotective effects of BDNF have been well doc-
umented, primarily in cultured cell systems, but also in
vivo. This includes studies demonstrating that BDNF
increases survival and has neuroprotective actions in
models of hypoxia, ischemia, excitotoxicity, hypoclycemia,
and inflammation
87-91; for reviews see refs 92,93. As dis-
cussed above, hippocampal pyramidal cell dendrite com-
plexity is decreased in BDNF Met allele or heterozygous
deletion mutants.
74 Similar effects have been observed in
PFC pyramidal cells, and stress does not produce further
atrophy of apical dendrites in BDNF heterozygous dele-
tion mutants, indicating that decreased BDNF underlies
the effects of stress.
73 These findings indicate that a full
complement of functional BDNF is required for mainte-
nance of normal dendritic arbor in both the hippocampus
and PFC. 
BDNF has also been shown to influence hippocampal
neurogenesis. Infusions of BDNF increase hippocampal
neurogenesis,
94,95 and BDNF is necessary for the survival
of new neurons in response to ADT.
96The BDNF recep-
tor, TrkB is also required for antidepressant induction of
hippocampal neurogenesis, as well as the behavioral
actions of antidepressants.
97 BDNF has also been impli-
cated in the behavioral actions of ADT. BDNF infusions
are sufficient to produce an antidepressant response in
rodent behavioral models of depression,
98-100 and mutant
mouse studies demonstrate that BDNF is required for
the behavioral actions of antidepressants.
75-77These find-
ings are consistent with the hypothesis that induction of
BDNF contributes to the neurogenic and behavioral
actions of antidepressants.
Other neurotrophic/growth factors
There is now strong evidence demonstrating a role for
several other growth factors in the actions of stress,
Neuroprotection and depression - Duman Dialogues in Clinical Neuroscience - Vol 11 . No. 3 . 2009
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growth factor (VEGF), fibroblast growth factor 2
(FGF2), and insulin-like growth factor 1 (IGF-1).
VEGF was originally characterized as a vascular per-
meability factor and an endothelial cell mitogen,
101 but is
also expressed in the brain in both neurons and glia, and
has been shown to play a role in hippocampal neuro-
plasticity, memory, and neurogenesis.
102,103 Chronic unpre-
dictable stress decreases the expression of VEGF, as well
as its receptor, Flk-1,
102 while ADT increases VEGF
expression in the granule cell layer of the hippocam-
pus.
104 Different classes of chemical antidepressants,
including SSRI, NSRI, and ECS, increase VEGF expres-
sion in the hippocampus, indicating that VEGF is a com-
mon downstream target of these treatments. 
The opposing actions of stress and ADT on VEGF sug-
gest a possible relationship between neurogenesis and
behavior. Stress has a greater effect on newborn cells
associated with endothelial cells than nonvascular asso-
ciated cells.
102 In addition, VEGF is sufficient to induce
neurogenesis and produce antidepressant effects in
behavioral models of depression, whereas inhibition of
Flk-1 blocks the induction of adult neurogenesis and the
behavioral effects of ADT.
104
A recent postmortem study found that the expression
of FGF2 and its receptors (FGFR2 and FGFR3) are
reduced in the PFC and cingulate cortex of MDD
patients,
105 and social defeat stress decreases FGF2 in
the hippocampus.
106 Conversely, chronic ADT increases
the expression of FGF2 in cerebral cortex and hip-
pocampus of rodents
107,108 and FGF2 infusions are suffi-
cient to produce an antidepressant response in behav-
ioral models.
109 The role of FGF2 in the proliferative
actions of ADT, on both neurons and glia, is currently
being investigated.
The expression of IGF-1 in the hippocampus is
increased by chronic administration of two different
monoamine oxidase inhibitor antidepessants.
110 In addi-
tion to expression in brain, circulating IGF-1, derived
primarily from the liver, is actively transported into the
brain and is required for the induction of neurogenesis
in response to exercise.
111 Recent studies have also
demonstrated that IGF-1 administration, or agents that
increase IGF-1 levels, produce antidepressant-like
actions in behavioral models of depression.
98,112,113
Together, these findings suggest that peripheral produc-
tion and/or the central actions of IGF-1 could be novel
targets for the treatment of depression.
Neuroprotective and neurotrophic effects of exercise
Exercise is reported to increase the expression of neu-
rotrophic/growth factors, including BDNF, VEGF,
FGF2, and IGF-1.
111,114-117 In addition, exercise increases
neurogenesis in the adult hippocampus, an effect that is
dependent on increased expression of IGF-1 and
VEGF.
111,114 IGF-1 has also been shown to underlie the
neuroprotective effects of exercise against different
types of brain insults.
118 In addition to the regulation of
these growth factors, exercise has also been shown to
influence other neuroprotective mechanisms.
119 These
positive, neuroprotective actions make exercise one of
the key behavioral factors for protecting, or even
reversing the damage that can be caused by environ-
mental, physical, and psychological stressors, and even
the susceptibility resulting from genetic vulnerabilities
(see Figure 1). 
Glutamatergic excitotoxicity: 
stress, depression, and ADT
Excess glutamatergic excitotoxicity is one of the major
mechanisms underlying neuronal damage and loss in the
brain, and has been implicated in the pathophysiology
of a variety of disorders, including those resulting from
acute insult (eg, stroke induced ischemia or trauma) and
neurodegenerative disorders (eg, amyotrophic lateral
sclerosis, Huntington’s chorea, epilepsy, and Alzheimer’s
disease.
120,121 This section discusses evidence for excess
glutamate in stress related mood disorders, the cellular
mechanisms that contribute to glutamate excitotoxicity,
and pharmacological strategies for intervention and
treatment.
Excess glutamate in depression and stress
Abnormal glutamate levels and function have been
implicated in psychiatric illnesses, including schizophre-
nia, anxiety, and mood disorders.
122-124 Glutamatergic
abnormalities have been reported in the plasma, serum,
cerebrospinal fluid (CSF), and brain tissue of individu-
als suffering from mood disorders.
123 Functional in vivo
measures of glutamate content in the brain using proton
magnetic resonance spectroscopy (H-MRS) show ele-
vated glutamate levels in the occipital cortex of
depressed patients, although decreases have been
reported in other regions.
123,125
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in the actions of stress. Microdialysis studies have shown
that stress increases extracellular levels of glutamate in
the PFC and hippocampus,
126,127 consistent with the pos-
sibility that atrophy of CA3 neurons arises in part
through increased glutamate neurotransmission.
128,129This
hypothesis is supported by studies demonstrating that
N-methyl-D-aspartic acid (NMDA) receptor antagonists
attenuate stress-induced atrophy of CA3-pyramidal neu-
rons.
29,32,130 Stress or glucocorticoid treatment also
increases the susceptibility to other types of neuronal
insults, including excitotoxins and ischemia.
129,131
There are several possible mechanisms that could con-
tribute to the overactivation of glutamate in response to
stress and in depression, including a decrease or loss of
mechanisms for inactivation of glutamate. Glial cells are
responsible for the reuptake and inactivation of gluta-
mate from synaptic and extrasynaptic sites.
123 Reductions
in the number or function of glia are thought to play a
role in the atrophy of limbic brain regions observed in
brain imaging studies, as well as decreased neuronal cell
body size in postmortem brains of depressed
patients.
123,132,133 Recent studies demonstrate that agents
that increase glial reuptake of glutamate, such as riluzole
and ceftriaxone, have antidepressant effects in rodent
behavioral models and in depressed patients.
132-134
Mechanisms of glutamate excitotoxicity
Glutamate neurotoxicity results from excessive flux of
Ca
2+ via ionoptopic receptors, including AMPA, kainiate,
and NMDA type receptors.
120,121,123 Uncontrolled eleva-
tion of intracellular Ca
2+ leads to further loss of Ca
2+
buffering and homeostasis, and then to a cascade of
events that contribute to cell damage and death. These
include oxidative stress resulting in generation of reac-
tive oxygen species (ROS) and nitric oxide, which results
in necrotic cell death characterized by swelling, mem-
brane damage, DNA degradation, and eventually
inflammation and cell lysis.
120,121,135
There are multiple sites for controlling glutamate release
and activity at pre- and postsynaptic sites, as well as for
buffering intracellular Ca
2+ that protects against cell
damage. These mechanisms are typically overcome only
by severe conditions, such as those that would occur dur-
ing stroke-induced ischemia, prolonged hypoxia, uncon-
trolled seizures or head trauma. As discussed above,
most studies do not report a loss of neurons in post-
mortem tissue from depressed patients, or in animal
models. However, excess glutamate is still thought to
play a role in psychiatric illnesses, and this has resulted
in targeting glutamatergic sites for development of ther-
apeutic agents for mood disorders, as well as for other
psychiatric, neurological, and neurodegenerative ill-
nesses.
Glutamate and neuroprotection: therapeutic targets
Glutamate neurotransmission is controlled by a complex
system of pre- and postsynaptic receptors, including
ionotropic and metabotropic subtypes. In addition, reg-
ulation of tropic factor signaling cascades, including
extracellular signal-related kinase (ERK), Akt, and
cAMP response element binding (CREB) can serve as
neuroprotective targets for excitoxicity. There is also evi-
dence that chronic ADT regulates the phosphorylation,
trafficking, and expression of glutamate receptors, pro-
viding further evidence that the actions of ADT involves
this neurotransmitter system. These topics have been
extensively covered by a number of recent
reviews.
121,123,136,137 A brief discussion of the major gluta-
matergic targets will be discussed here.
One of the key targets for regulation of glutamate is glial
reuptake, which is the primary mechanism for inactiva-
tion of glutamate neurotransmission. Agents that
increase this process, notably riluzole and ceftriaxone, are
reported to have antidepressant efficacy in rodent mod-
els and in clinical trials.
123,132,138These effects are mediated
in part by increased expression of glial excitatory amino
acid transporters. Riluzole also has several other inter-
esting properties, including the ability to decrease glu-
tamate and increase neurotrophic factor expression,
making this an interesting, and potentially useful thera-
peutic compound. Clinical and preclinical studies are cur-
rently underway to further test the therapeutic efficacy
and mechanisms underlying the actions of riluzole.
Lamotragine is another compound that acts in part by
decreasing glutamate release and is used for treating
mood disorders, although with limited efficacy.
123
Blockade of the NMDA ionotropic receptor represents
another primary target for neuroprotection, although
this is a complex issue as glutamate is the major excita-
tory neurotransmitter in the brain. However, agents that
block the NMDA channel, most notably memantine and
ketamine, are reported to have antidepressant actions in
clinical trials and rodents.
123,137The actions of memantine
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ministered with other antidepressants. However, reports
on ketamine have been extraordinary, with several stud-
ies demonstrating a rapid and sustained antidepressant
response in approximately 60% of patients tested, which
have all been resistant to other chemical antidepres-
sants.
139,140 A single intravenous dose of ketamine, which
produces transient and mild psychotomimetic effects,
results in an antidepressant response within 6 to 12
hours, and this effect is sustained for at least 7 days.
These effects are dramatic compared with all other
chemical antidepressants, which require weeks or
months of treatment before a therapeutic response is
observed. Further studies are needed to identify safer
drugs that have rapid antidepressant effects similar to
ketamine.
The most direct mechanism to explain the antidepres-
sant action of ketamine is its direct inhibitory effect on
NMDA receptors. In particular, the hypothesis that
blockade of the extrasynaptic NR2B receptor subtype,
which is activated by excess glutamate, underlies the
therapeutic action of ketamine has received the most
attention. This possibility is supported by a recent study
demonstrating that a selective NR2B receptor inhibitor,
CP-101,606, produces a rapid antidepressant response in
treatment resistant MDD patients.
141 Another possible
mechanism to account for the rapid actions of these
agents is via blockade of NMDA receptors on
GABAergic inhibitory neurons, which leads to disinhi-
bition or activation of glutamatergic transmission. The
latter possibility is supported by studies in rodents
demonstrating that NMDA channel blockers increase
BDNF expression in limbic structures, indicating stimu-
lation of neuronal activity,
142,143 and by a recent report
that the behavioral actions of ketamine are blocked by
inhibition of AMPA receptor activity.
144
The metabotropic glutamate receptors represent another
interesting and diverse set of targets for drug develop-
ment.
123,136 Group I receptors, particularly mGluR1/R5
subtypes located at postsynaptic sites as well as on glia,
influence both the function and release of glutamate.
Drugs acting at these receptors are reported to have anx-
iolytic effects in rodent models. Group II receptors,
mGluR2 and R3, located at presynaptic sites and on glia
and regulate glutamate release, have also been targets of
interest. Both agonists and antagonists of group II recep-
tors have shown promise, with reports that mGluR2/R3
antagonists have antidepressant actions and agonists
showing anxiolytic and antipsychotic effects. Most
promising is a clinical report demonstrating antipsychotic
efficacy of an mGluR2/3 agonist.
145
Allosteric AMPA receptor potentiator (ARP) agents
make up another interesting group of drugs. These agents
do not directly stimulate AMPA receptors, but slow the
inactivation or desensitation of the receptors. The idea of
using drugs that enhance AMPA receptor function would
appear to be counterintuitive given the possibility of an
overactive glutamate system. However, preclinical stud-
ies of these agents, which were first developed for
enhancing cognition, demonstrate positive antidepres-
sant-like effects in rodent models of depression.
123,146
Programmed cell death (apoptosis) 
in stress and depression
Programmed cell death is a critical mechanism for reg-
ulation of the appropriate complement of neurons dur-
ing development, but apoptotic signaling pathways are
also regulated in the adult brain and influence the num-
ber and function of mature cells. Apoptosis is a highly
regulated signaling process, which includes the Bcl-2 fam-
ily of proteins, cytochrome C, a cytosolic adaptor protein,
and caspase activation, which results in energy-depen-
dent death.
135,147The Bcl-2 family includes antiapoptotic
factors (ie, Bcl-2 and Bcl-xl) that antagonize proapoptotic
factors (eg, Bax and Bak). Upon activation of apoptotic
pathways, Bax and Bak insert into the mitochrondrial
membrane and promote the release of cytochrome C,
which in turn binds to the apoptotic activator factor
(Apaf1), leading to activation of capases 9 and 3. 
Regulation of apoptosis by depression, stress, and
ADT
Analsysis of postmortem tissue and rodent models has
provided some evidence for apoptotic cell death and/or
signaling in depression and stress.
135 There is a post-
mortem report of low levels of apoptosis in the tempo-
ral cortex and hippocampus of depressed patients.
148
Rodent studies demonstrate that social stress increases
the number of apoptotic cells in the hippocampus and
temporal cortex,
149 and chronic unpredictable stress
increases the number of caspase 3 positive neurons in
the cerebral cortex.
150 Maternal separation of rats is also
reported to increase cell death in the dentate gyrus of
hippocampus.
151
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for a link between apoptosis signaling and depression.
Polymorphisms of the adaptor protein Apaf1 were found
to be associated with major depression.
152 These poly-
morphisms increase the activity of caspase 9 and would
thereby increase the vulnerability of neurons to apop-
totic cell death. 
There are also several studies that have examined levels
of apoptotic signaling proteins in models of stress and
ADT. Chronic unpredictable stress is reported to
decrease levels of the antiapoptotic factors Bcl-2 and
Bcl-xl, but does not influence levels of Bax.
153
Administration of a high dose of adrenal-glucocorticoids
reduces Bcl-2 levels, and this effect corresponds with
increased sensitivity to excitotoxic damage.
154 Conversely,
chronic ADT increases the expression of Bcl-2 and/or
Bcl-xl in limbic brain regions.
153,155,156 Chronic administra-
tion of lithium or valproate also increases Bcl-2 in the
hippocampus and PFC.
157 The antiapoptotic actions of
lithium and valproate have also been demonstrated in
studies of cultured cells.
158-160
Antidepressants also influence other signaling cascades
that indirectly influence apoptotic processes. Most
notable are the effects of stress and ADT on neu-
rotrophic factors and related signaling cascades, includ-
ing ERK and Akt, which increase cell survival in part via
inhibition of apoptotic, and induction of antiapoptotic
factors such as Bcl-2.
135,161 Finally, it is also notable that
certain members of the Bcl-2 family have also been
implicated in other cellular functions, including neuro-
transmission, which could be involved in the actions of
stress and ADT.
162
Mitochondria play a primary role in the storage, pro-
cessing, and release of proteins involved in apoptosis,
and recent studies demonstrate a role for other aspects
of mitochondria function in the pathophysiology and
treatment of mood disorders.
154,163
Inflammation/immune responses
Inflammation and immune responses are major factors
contributing to the etiology and pathophysiology of
many medical illnesses, including depression and other
psychiatric disorders. Inflammation can be caused by
other medical conditions, including infection, stroke,
trauma, and abnormal or autoimmune responses.
However, it is also now clear that psychological stress,
such as social stress, can activate the innate immune sys-
tem, elevating cytokine production, and thereby stimu-
late inflammatory processes.
164-167
Inflammatory and immune processes can lead to multi-
ple actions that have acute protective actions, but that
also can have damaging effects on cells and tissue. This
includes many of the same actions implicated in the
responses to stress and depression, including activation
of the HPA axis, alterations of neurotransmitter systems,
decreased neurotrophic factor expression, and increased
oxidative stress.
167 Depending on the severity and length
of the inflammatory response, these effects can result in
significant actions on neuronal and glial function and cell
survival or death. 
There are several proinflammatory cytokines of interest,
including IL-1, IL-6, and tumor necrosis factor (TNF)α,
that have been implicated in the pathophysiology and
treatment of depression. Also of interest are studies of
interferon-α, used for the treatment of hepatitis or can-
cer, which results in depressive-like symptoms in a large
number of patients. Here we discuss a few of the most
interesting targets for treatment of depression; for a
more thorough review see ref 167.
TNFα and depression
One of the most consistently altered proinflammatory
cytokines in depressed subjects is TNFα. An inverse cor-
relation between levels of TNFα and treatment response
has been reported.
168,169TNFα immunotherapy also causes
depression, indicating that this cytokine may contribute
to the etiology of mood disorders and is not simply a
marker for depression (for reviews see refs 168,170).
Moreover, a recent large clinical trial using an antibody
neutralization approach demonstrated significant anti-
depressant effects of TNFα reduction.
171This finding is
supported by preclinical studies demonstrating that
TNFα infusions produce a prodepressive effect,
172 and
that TNFα receptor null mutant mice have an antide-
pressant phenotype in the forced swim and sucrose con-
sumption tests.
173Taken together, the preclinical and clin-
ical studies provide strong support for TNFα receptors,
particularly TNFR2, as targets for the treatment of mood
disorders.
IL-1β, stress, and depression
There is also strong evidence that the proinflammatory
cytokine IL-1β plays a key role in the pathophysiology of
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relevant target for drug development.
174,175These findings
include: i) clinical studies reporting an increase in serum
levels IL-1β in MDD
176-180; ii) reports that IL-1β produces
stress like effects, including activation of the HPA axis,
regulation of monoamines, and behavioral responses in
rodent models
181; iii) evidence that IL-1β contributes to
conditioned fear and depressive like behavior,
182 and pro-
duces anhedonia and disrupts incentive motivation in
rodent models
183; iv) preclinical reports that IL-1β
decreases hippocampal neurogenesis and underlies the
decrease observed in response to stress
184; v) our report
that CUS-induced anhedonia and decreased neurogene-
sis produced by is blocked by pharmacological inhibition
or null mutation of IL-1β receptors.
184 Studies are cur-
rently underway to determine if blockade of peripheral,
as well as central IL-1β signaling is sufficient to block the
effects of stress and produce antidepressant actions.
Interferon and IDO
Recent studies demonstrate that one of the key factors
contributing to the depressive actions of inflammation and
activation of the innate immune system is the induction of
a tryptophan degradative enzyme, indoleamine 2,3-dioxy-
genase (IDO). Chronic inflammation and infection can
lead to sustained induction of interferon, which is then
responsible for the increased levels of IDO. The induction
of IDO then results in diversion of tryptophan from the
synthesis of serotonin to kyneurenic acid, which can be fur-
ther converted to toxic metabolites, most notably quino-
linic acid. Evidence for IDO in depression is supported by
studies demonstrating that decreased levels of tryptophan
and increased kyneurenin is associated with inflammation
and depression.
185 Increased IDO has also been positively
correlated with depression, although a direct causal rela-
tionship has not been demonstrated. 
A recent study has now provided direct evidence that
induction of IDO underlies the depressive behaviors
caused by inflammation/activated immunologic conditions.
This work was conducted using a bacterial immune acti-
vation model, Bacille Calmette-Guerin (BCM), which
induces a long-lasting induction of interferon and results
in depressive behaviors in animal models.
185,186The results
demonstrate that BCM-mediated immobility in the forced
swim test is reversed by an IDO inhibitor, 1-methyltryp-
tophan, and in mice that are deficient in IDO.
185 In addi-
tion, BCM also increases the expression of a downstream
enzyme, 3-hydroxyanthranilic acid oxygenase (3-HAO)
that is involved in the synthesis of quinolinic acid. These
studies indicate that an IDO inhibitor, and possibly an
inhibitor of 3-HAO, could have efficacy for the treatment
of depression and related mood disorders. 
Summary and future directions
Significant advances have been made in characterizing the
neuronal and glial damage, or structural alterations, at the
cellular and anatomical levels in stress-related mood dis-
orders and other psychiatric illnesses, and in elucidating
the molecular signaling pathways and mechanisms that
underlie these changes. However, this work is still at a rel-
atively early stage, and a more complete characterization
of these complex alterations and signaling mechanisms
will require extensive resources and time. Moreover, iden-
tification of genetic polymorphisms that impact these
pathways and systems and that influence susceptibility or
resilience to illness is a major area of research that will
continue to develop and unfold. When combined with
studies of environmental risk factors and lifetime history
of stress, this work will define and describe the mecha-
nisms underlying individual variations of illness. 
Together, the results of this work can be used to formu-
late a comprehensive approach for the prevention and
treatment of psychiatric illnesses. Changes in lifestyle
and behavior can reduce stress and exposure to envi-
ronmental factors that influence cellular risk and dam-
age and prevent illness. These approaches, as well as
behavioral interventions that enhance the activity and
function of specific neural circuits, and thereby provide
protection, can also be used once a person has become
ill. Development of therapeutic agents that target neu-
roprotective mechanisms, combined with genetic infor-
mation will ultimately provide tailored approaches for
highly specific and efficacious treatments for depression
and other illnesses.  ❏
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Daño y protección neuronal en la fisiopatología
y el tratamiento de la enfermedad psiquiátrica:
el estrés y la depresión 
El haber descubierto que el estrés y la depresión,
al igual que otras enfermedades psiquiátricas, se
caracterizan por alteraciones estructurales, y que
estos cambios se deben a atrofia y pérdida de neu-
ronas y glía en regiones y circuitos límbicos especí-
ficos ha contribuido a un cambio fundamental en
la comprensión de estas enfermedades. Estos cam-
bios estructurales se acompañan de una falta de
regulación de los mecanismos de señales neuro-
protectoras y neurotróficas, los cuales son requeri-
dos para la maduración, crecimiento y superviven-
cia de las neuronas y la glía. A la inversa, las
intervenciones conductuales y terapéuticas pueden
revertir estas alteraciones estructurales mediante
la estimulación de las vías neuroprotectoras y neu-
rotróficas y a través del bloqueo de los efectos
dañinos, excitotóxicos e inflamatorios del estrés. La
exposición a lo largo de la vida a estresores celula-
res y ambientales, y las interacciones con factores
genéticos contribuyen a la susceptibilidad o a la
resiliencia.  Esta interesante área de investigación
abriga potenciales esperanzas para favorecer la
dilucidación de la fisiopatología de las enfermeda-
des psiquiátricas y el desarrollo de nuevas inter-
venciones terapéuticas.
Lésions et protection neuronales dans la 
physiopathologie et le traitement des 
maladies psychiatriques : stress et dépression
Notre compréhension du stress et de la dépression,
comme d’autres maladies psychiatriques, a été pro-
fondément transformée en découvrant que ces
maladies sont caractérisées par des modifications
structurales résultant de l’atrophie et de la perte
des neurones et de la glie dans des régions et des
circuits limbiques spécifiques. Ces modifications
structurales s’accompagnent d’une dysrégulation
des mécanismes de signalisation neurotrophiques
et neuroprotecteurs nécessaires à la maturation, la
croissance et la survie des neurones et de la glie. À
l’opposé, des interventions comportementales et
thérapeutiques peuvent inverser ces modifications
structurales en stimulant les voies neuroprotectrices
et neurotrophiques et en bloquant les effets lésion-
nels, excitotoxiques et inflammatoires du stress.
L’exposition durant la vie aux agents stressants cel-
lulaires et environnementaux et les interactions
avec des facteurs génétiques participent à la sus-
ceptibilité individuelle ou à la résilience. Ce
domaine de recherche passionnant est prometteur
et devrait permettre d' expliquer plus précisément
la physiopathologie des maladies psychiatriques et
de participer au développement de nouveaux trai-
tements.
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